However, the gold standard treatment proposed for patients with AMD is based on limiting the function of the vascular endothelial growth factor (VEGF) [18,19,20] via intravitreal injection of anti-VEGF molecules, which were found to be effective in avoiding the loss of visual function and stabilizing disease progression [18,21,22,23,24,25,26,27]. This evidence concerns the gene VEGFA and age-related macular degeneration.